Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19
In the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retros...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/8/1551 |
id |
doaj-9f66fbc6825144978e43a180deb413a7 |
---|---|
record_format |
Article |
spelling |
doaj-9f66fbc6825144978e43a180deb413a72021-04-07T23:03:41ZengMDPI AGJournal of Clinical Medicine2077-03832021-04-01101551155110.3390/jcm10081551Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19Marta Bodro0Frederic Cofan1Jose Ríos2Sabina Herrera3Laura Linares4María Angeles Marcos5Alex Soriano6Asunción Moreno7Fritz Diekmann8Infectious Diseased Department, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Hospital Clinic, 08036 Barcelona, SpainDepartment of Nephrology and Renal Transplantation, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Hospital Clinic, 08036 Barcelona, SpainMedical Statistics Core Facility, Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, 08193 Bellaterra, SpainInfectious Diseased Department, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Hospital Clinic, 08036 Barcelona, SpainInfectious Diseased Department, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Hospital Clinic, 08036 Barcelona, SpainMicrobiology Department, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Hospital Clinic, 08036 Barcelona, SpainInfectious Diseased Department, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Hospital Clinic, 08036 Barcelona, SpainInfectious Diseased Department, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Hospital Clinic, 08036 Barcelona, SpainDepartment of Nephrology and Renal Transplantation, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona and Hospital Clinic, 08036 Barcelona, SpainIn the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retrospective study, which included patients from March to May 2020. An inverse probability of treatment weighting from a propensity score to receive AT was used in all statistical analyses, and we applied a bootstrap procedure in order to calculate an estimation of the 2.5th and 97.5th percentiles of odds ratio (OR). outcomes were measured using an ordinal scale determination (OSD). A total of 33 kidney recipients required hospitalization and 54% of them received at least one AT, mainly tocilizumab (42%), followed by anakinra (12%). There was no statistical effect in terms of intensive care unit (ICU) admission, respiratory secondary infections (35% vs. 7%) or mortality (16% vs. 13%) comparing patients that received AT with those who did not. Nevertheless, patients who received AT presented better outcomes during hospitalization in terms of OSD ≥5 ((OR 0.31; 2.5th, 97.5th percentiles (0.10; 0.72)). These analyses indicate, as a plausible hypothesis, that the use of AT in kidney transplant recipients presenting with COVID-19 could be beneficial, even though multicenter randomized control trials using these therapies in transplanted patients are needed.https://www.mdpi.com/2077-0383/10/8/1551COVID-19kidney transplantationanti-cytokine therapymortalityinfection |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Marta Bodro Frederic Cofan Jose Ríos Sabina Herrera Laura Linares María Angeles Marcos Alex Soriano Asunción Moreno Fritz Diekmann |
spellingShingle |
Marta Bodro Frederic Cofan Jose Ríos Sabina Herrera Laura Linares María Angeles Marcos Alex Soriano Asunción Moreno Fritz Diekmann Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19 Journal of Clinical Medicine COVID-19 kidney transplantation anti-cytokine therapy mortality infection |
author_facet |
Marta Bodro Frederic Cofan Jose Ríos Sabina Herrera Laura Linares María Angeles Marcos Alex Soriano Asunción Moreno Fritz Diekmann |
author_sort |
Marta Bodro |
title |
Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19 |
title_short |
Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19 |
title_full |
Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19 |
title_fullStr |
Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19 |
title_full_unstemmed |
Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19 |
title_sort |
use of anti-cytokine therapy in kidney transplant recipients with covid-19 |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2021-04-01 |
description |
In the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retrospective study, which included patients from March to May 2020. An inverse probability of treatment weighting from a propensity score to receive AT was used in all statistical analyses, and we applied a bootstrap procedure in order to calculate an estimation of the 2.5th and 97.5th percentiles of odds ratio (OR). outcomes were measured using an ordinal scale determination (OSD). A total of 33 kidney recipients required hospitalization and 54% of them received at least one AT, mainly tocilizumab (42%), followed by anakinra (12%). There was no statistical effect in terms of intensive care unit (ICU) admission, respiratory secondary infections (35% vs. 7%) or mortality (16% vs. 13%) comparing patients that received AT with those who did not. Nevertheless, patients who received AT presented better outcomes during hospitalization in terms of OSD ≥5 ((OR 0.31; 2.5th, 97.5th percentiles (0.10; 0.72)). These analyses indicate, as a plausible hypothesis, that the use of AT in kidney transplant recipients presenting with COVID-19 could be beneficial, even though multicenter randomized control trials using these therapies in transplanted patients are needed. |
topic |
COVID-19 kidney transplantation anti-cytokine therapy mortality infection |
url |
https://www.mdpi.com/2077-0383/10/8/1551 |
work_keys_str_mv |
AT martabodro useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT fredericcofan useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT joserios useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT sabinaherrera useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT lauralinares useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT mariaangelesmarcos useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT alexsoriano useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT asuncionmoreno useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 AT fritzdiekmann useofanticytokinetherapyinkidneytransplantrecipientswithcovid19 |
_version_ |
1721535651633954816 |